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Abstract 
 Hypertensive disorders of pregnancy can have negative effects on both 
mothers and neonates and are a major contributor to the increasing morbidity and 
mortality affecting women pregnant women in the United States.  Treatment 
algorithms are available for treatment of hypertensive disorders of pregnancy 
when treatment criteria are met.  With proper use of these algorithms, healthcare 
personnel can decrease the mortality and morbidity rates, which will increase 
patient safety and decrease healthcare spending.  This research project focused on 
implementing The American College of Obstetricians and Gynecologists’ 
(ACOG) Labetalol treatment algorithm to treat patients diagnosed with severe 
preeclampsia.  Prior to implementation, data was collected from November 1, 
2018 through January 31, 2019 and compared to data that was collected after 
implementation, March 1, 2019 through May 31, 2019.  Although compliance 
with algorithm utilization decreased post implementation, the data proves that 
with proper use, the Labetalol algorithm improves maternal blood pressures and 
maternal outcomes. 
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Improving Maternal Outcomes through Labetalol Algorithm Utilization for 
Hypertensive Disorders of Pregnancy 
Hypertensive disorders of pregnancy continue to be a key contributor to 
mortality and morbidity in pregnant women in the United States.  According to 
Collier & Martin (2018), 7.4% of the 800 pregnancy related deaths that occur 
each year are hypertension related.  Not only do these disorders affect the 
pregnant female, but they can have a negative effect on the neonate as well; 
leading to preterm delivery, fetal growth restriction, and perinatal mortality.  In 
1993, hypertensive disorders affected approximately 500 per 10,000 delivery 
hospitalizations compared to 900 per 10,000 in 2014 (CDC, 2018).  Prompt 
treatment of hypertensive disorders of pregnancy with a recommended 
hypertensive medication use can decrease mortality and morbidity significantly if 
implemented appropriately (ACOG, 2013). 
Hypertensive disorders of pregnancy are separated into four different 
classifications: chronic hypertension, gestational hypertension, preeclampsia and 
eclampsia, chronic hypertension plus superimposed preeclampsia.  Chronic 
hypertension is defined as a systolic blood pressure (SBP) of greater than 140 or a 
diastolic blood pressure (DBP) greater than 90 that occurs prior to pregnancy or 
before 20 weeks gestation (American Congress of Obstetricians and 
Gynecologists [ACOG], 2017).  Gestational hypertension is defined as a SBP 
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greater than 140 or a DBP greater than 90 that occurs after 20 weeks gestation 
with no detection of proteinuria or other systemic signs/symptoms (ACOG, 2017).  
Preeclampsia is defined as a SBP greater than 140 or a DBP of 90 with the 
presence of proteinuria with or without systemic signs/symptoms; or the 
presentation of systemic signs/symptoms/lab abnormalities in the absence of 
proteinuria (ACOG, 2017).  Chronic hypertension plus superimposed 
preeclampsia is defined as the presence of chronic hypertension in addition to the 
development of proteinuria or systemic signs/symptoms/lab abnormalities (See 
Appendix A).  Signs/symptoms of severe features of preeclampsia include: Two 
severe blood pressure values obtained 15-60 minutes apart (SBP ≥ 160 or DBP ≥ 
110), persistent oliguria <500mL/24 hours, progressive renal insufficiency, 
unremitting headache/visual disturbances, pulmonary edema, epigastric of right 
upper quadrant (RUQ) pain, liver function tests (LFTs) > 2x the normal value, 
platelets < 100,000, and the development of HELLP (hemolysis, elevated liver 
enzymes, and low platelet counts) syndrome (ACOG, 2017).  HELLP syndrome is 
a life-threatening emergency.   
Early detection of hypertensive disorders of pregnancy and appropriate 
management can improve outcomes for both the pregnant female and the neonate.  
Missed opportunities for recommended care contribute to the morbidity and 
mortality. ACOG (2018) provides recommendations for diagnostic criteria, 
treatment implications, medications (such as Labetalol), and monitoring.  These 
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recommendations are available for adoption and use in healthcare settings 
throughout the United States and have proven to improve maternal and fetal 
outcomes; however, many facilities lack an evidence-based maternal safety 
bundle. The purpose of this project is to describe the care of pregnant women with 
preeclampsia following the establishment of a protocol for use of the Labetalol 
Algorithm. 
 The aims of this project were to establish baseline data on the number of 
diagnosed preeclamptic patients that required treatment and how quickly 
treatment was implemented; disseminate this data to physicians; and implement a 
Labetalol Algorithm for treatment to improve maternal outcomes.  On 
completion, this project answered the following PICOT questions: In pregnant 
women aged 18-45 at a Midwestern, suburban hospital, 
1. What is the rate of the Labetalol Algorithm use by physicians when 
criteria are met for preeclampsia? 
2. When criteria are met, how quickly was treatment initiated? 
3. When criteria are met for severe preeclampsia and treatment is 
initiated, what is the rate of maternal blood pressure (BP) 
improvement (return to patient baseline) pre and post algorithm? 
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4. What is the rate of unplanned cesarean section when diagnosis of 
preeclampsia is met before the Labetalol Algorithm was implemented 
compared to after? 
Review of Literature 
Using truncation from October 1, 2010 to October 31, 2018, a literature 
search was conducted using the following databases: CINAHL, Consumer Health 
Complete, eBook Clinical Collection, MEDLINE, and Cochrane.  The terms used 
to conduct the search were “ACOG guidelines for hypertensive disorders of 
pregnancy,” and “labetalol.”  The search resulted 57 articles.  After reviewing the 
titles of the articles, 17 articles were chosen for abstract review based on 
relevance to current pharmacological treatment recommendations.  After further 
review of these articles, five were excluded that only contained data on neonatal 
outcomes during hypertensive emergencies in intrapartum patients. 
 The percentage of pregnancies affected by hypertensive disorders ranged 
from 2.3% to 15% and are becoming more prevalent leading to an increased rate 
of maternal mortality and morbidity (Anderson & Schmella, 2017; Arukumarlan 
& Lighthouse, 2013; Cairns et al., 2016; Delgado De Pasquale, Velarde, Reyes, & 
De La Ossa, 2014; Kelley, 2012; Vadhera & Simon, 2014).  In the United States, 
hypertensive disorders of pregnancy led to the death of 256 women in a three-year 
time span, whereas eclampsia contributes to an estimated 50,000 deaths each year 
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worldwide (Kelley, 2012).  Between the years 1990-2015 in the United States, 
maternal morality rose by as much as 27% (Collier & Martin, 2018).   
ACOG’s report titled Hypertension in Pregnancy (2013) asserts that for 
every maternal death due to hypertension that there is nearly 50-100 “near 
misses” that result in serious health consequences for the mother which 
contributes to the increasing costs of healthcare. Preeclampsia has the potential to 
affect multiple organ systems leaving the woman susceptible to multiple 
morbidities including: disseminated intravascular coagulation and respiratory, 
cardiovascular, cerebrovascular, liver, kidney, uterine, and neurologic 
complications (Anderson et al., 2013; Kelley, 2012).  Kilpatrick et al. (2016) 
compared morbidity rates between women with acute severe intrapartum 
hypertension (2252 women) and women without severe hypertension (93,560 
women).  This retrospective cohort study found that severe maternal morbidities 
were more frequent in women with severe hypertension (8.8%) as opposed to the 
control group (2.3%).  However, morbidities were present in only 8.6% of severe 
hypertensive women that received treatment as opposed to 9.5% of the women 
who didn’t receive treatment (Kilpatrick et al., 2016).   
Risk factors for the development of hypertensive disorders of pregnancy 
include: type 1 diabetes, gestational diabetes, other endocrine disorders, chronic 
hypertension, kidney disease, connective tissue disease, multiple gestation, molar 
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pregnancy, pre-pregnancy obesity, increased SBP in early pregnancy, extremes of 
reproductive age, and a personal or family history of preeclampsia (Kelley, 2012).  
In a cross-sectional study by Omani-Samani et al. (2017), the rate of preeclampsia 
was higher in women who had a significant weight gain during their pregnancy 
compared to women who gained an appropriate amount of weight.  In this study, 
the women with preeclampsia also showed higher rates of preterm birth, cesarean 
section, and low birth weight infants. 
  In the past, there has been a lack of data on the safety and efficacy of 
hypertensive drugs when used during pregnancy.  This has contributed to the 
large variations in practice guidelines globally.  However, in recent years the 
diagnosis and treatment of these disorders has been modified by ACOG (Vadhera 
& Simon, 2014).  Clark et al.’s report (2014) showed a significant reduction in 
morbidity when order sets and protocols were implemented in facilities.  Amro, 
Moussa, Ashmini, & Sibai (2016) recommend a step-wise approach when 
diagnosing and treating hypertensive disorders or pregnancy.  Like Delgado De 
Pasquale et al. (2014), Amro et al. (2016) recommend maxing out the use of one 
medication prior to the use of a second antihypertensive.  One prospective, 
randomized, controlled trial utilized the Hydralazine and Labetalol protocols that 
were identical to the example protocol provided in the Maternal Safety Bundle 
provided by ACOG.  A total of 261 participants were included in the study 
(Hydralazine group: n=131 and Labetalol group: n=130).  Prior to utilization of 
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the algorithm, the initial SBP, DBP, and Mean Arterial Pressure (MAP) for the 
Hydralazine group were as follows: 170 mmHg, 108 mmHg, and 128 mmHg.  
After the protocol was implemented, their readings saw improvements: 144 
mmHg (SBP), 91 mmHg (DBP), and 109 mmHg (MAP).  The same held true for 
the Labetalol group.  The results prior to treatment were 172 mmHg (SBP), 107 
mmHg (DBP), and 129 mmHg (MAP). After treatment, the values improved to 
144 mmHg (SBP), 92 mmHg (DBP), and 109 mmHg (MAP).  This study 
concluded that Hydralazine or Labetalol has efficacy in controlling hypertensive 
crises; however, the study concluded that there was persistent hypertension with 
the use of Hydralazine (4.6%) compared to Labetalol (1.5%) (Delgado De 
Pasquale et al., 2014).  In the report Hypertension in Pregnancy by ACOG 
(2013), it discusses that a Cochrane systematic review was conducted and that 
there was no significant difference between the safety and efficacy of Labetalol 
and Hydralazine.  ACOG (2013) encourages the use of the drug that the physician 
and facility is most familiar and comfortable with.  For this project, the drug of 
choice will be Labetalol due to familiarity and facility preference. 
 A cohort study by Xie et al. (2013) concluded that there has been an 
increase use in antihypertensive drugs in pregnancy.  According to the survey 
conducted by Cairns et al. (2016), Labetalol was the most used antihypertensive 
(91% of physicians). When compared to physicians, midwives stated that they 
had a lower threshold for reducing antihypertensive medications than physicians.  
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This study concluded that there is lack of consistency present in the management 
of hypertensive patients.  This may be the result of lack of evidence or guidance.  
ACOG (2013) points out that there have been major advances in the knowledge 
surrounding hypertensive disorders of pregnancy as well as new evidence that can 
guide therapies and management.  However, these new advancements have not 
made their way into clinical practices yet.  This is where the importance of 
adopting and implementing treatment algorithms is crucial in the management of 
these patients. 
Treatment Recommendations 
Prompt triage and assessment of pregnant women presenting with 
hypertension is crucial for earlier diagnosis and treatment.  A full of review of 
systems should be performed to evaluate for cardiovascular symptoms (chest 
pain), neurological symptoms (headache or visual disturbances), consciousness, 
and difficulty breathing (Vadhera & Simon, 2014).  When triaging a hypertensive 
patient, baseline labs must be ordered and include:  complete blood count (CBC) 
with differential and platelet count, comprehensive metabolic panel (CMP), 
urinalysis (UA), and a protein/creatinine ratio (ACOG, 2017; Kelley, 2012; 
Vadhera & Simon, 2014).  If end organ involvement is detected, pharmacologic 
treatment and continuous monitoring is warranted.  If the fetus is at a viable 
gestation (>23 weeks), continuous fetal monitoring is recommended (ACOG, 
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2017; Vadhera & Simon, 2014).  When using the ACOG suggested Labetalol 
algorithm, maternal blood pressure and pulse should be measured at least every 
10 minutes until stable (ACOG, 2017; Vadhera & Simon, 2014).  Once stable, 
blood pressure should be monitored according to ACOG recommendations (see 
Appendix D) (ACOG, 2017).  If a diagnosis of severe preeclampsia is made and 
pharmacologic treatment has been initiated, depending on gestation, consult 
should be made to anesthesiology and maternal fetal medicine (Vadhera & Simon, 
2014).  Once diagnosis has been made, the objectives of treatment are the 
prevention of seizures (eclampsia), tight blood pressure control, and the plan for 
delivery (Peres, Mariana, & Cairrao, 2018). Maternal indications for delivery 
include: “recurrent severe hypertension, recurrent symptoms of preeclampsia, 
progressive renal insufficiency, persistent thrombocytopenia of HELLP 
syndrome, pulmonary edema, eclampsia, suspected abruptio placentae, or 
progressive labor or rupture of membranes” (ACOG, 2013, p.39). Transfer to a 
tertiary care center may be necessary for services for the mother and neonate. 
 For this Quality Improvement (QI) project, a Plan-Do-Study-Act (PDSA) 
framework was used to implement change.  A PDSA is a four-stage cycle 
approach that aids in the adaptation of changes.  The first stage includes the 
identification of the change followed by the testing of the change in the “do” 
phase.  The third stage identifies if the change was successful followed by making 
necessary modifications in the fourth stage.  PDSA approaches have demonstrated 
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significant improvements in the care patients receive and their outcomes (Taylor 
et al., 2013).   
Methods 
Design 
 A descriptive study design was for this quality improvement project.  A 
quality improvement process using the Plan-Do-Study-Act (PDSA) cycle was 
used to implement the Labetalol Algorithm. 
Setting 
 An inpatient women’s services unit at an organizationally owned hospital 
in a suburb of a metropolitan area that is home to over three million people.  This 
unit employs more than 40 staff nurses and a team of more than 15 house 
obstetricians.  While not employed by the hospital, more than 30 private 
physicians have practice rights to perform services at this setting.  This unit is 
open 24 hours a day and 365 days a year.  Delivery services are offered to 
pregnant patients who have completed at least the 32nd week of gestation.  
Women who present to this unit who are less than 32 weeks gestation and are in 
stable condition are transferred to a tertiary care center.  This unit performs 
approximately 75 deliveries per month and did 828 deliveries last year. 
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Sample 
 A convenience sample of antepartum, intrapartum, or postpartum patients 
whom are at least 32 weeks gestation or greater was used.  The study period was 
March 1st through May 31st.  Inclusion criteria included pregnant females between 
the ages of 18-45 who are greater than 32 weeks of gestation with a known or 
newly diagnosed hypertensive disorder of pregnancy.  Exclusion criteria included 
non-pregnant females, pregnant females below the age of 18 and above the age of 
45, and pregnant females less than 32 weeks gestation that require transfer to a 
tertiary care center. 
Approval Process 
 This project was approved by the Assistant Nurse Manager and Manager 
at Progress West Hospital in the Women’s Services department at the beginning 
of Semester 2018.  The Labetalol algorithm was approved for use by the house 
Obstetrician at Progress West as well as the Chief Medical Officer of the 
department in October 2018.  It was submitted to the University of Missouri-St. 
Louis (UMSL) College of Nursing doctoral committee and UMSL graduate 
school for approval. In addition, UMSL Institutional Review Board (IRB) 
approval was obtained.   
The benefits of this project included: standardization of evidence-based 
care for hypertensive patients; decreased rates of eclampsia with prompt 
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treatment; and increased awareness of treatment and management of hypertensive 
disorders by all healthcare personnel. 
Data Collection 
 Prior to implementation of the Labetalol algorithm, data was collected via 
a retrospective chart review from November 1st 2018 through January 31st, 2019 
to determine the current treatment of hypertensive antepartum females using the 
data collection tool (Appendix E).  The chart review contained data extracted 
from the medical record that contained: weeks of gestation, vital signs, time from 
diagnosis to treatment, medication and dose administered, and method of delivery 
of the fetus.  After implementation of the Labetalol algorithm, retrospective chart 
review occurred once a week from March 1, 2019 to May 31, 2019 to allow for 
statistical analysis of pre and post intervention data and dissemination of results.   
Data collected was de-identified and coded. Charts reviewed prior to the 
new protocol were labeled “B” for baseline beginning with B1.  Charts reviewed 
following implementation of the Labetalol algorithm were labeled “A” beginning 
with A1.  All data was stored on a password protected computer and encrypted 
USB flash drive. This information was deleted after completion of the project in 
July 2019.  
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Procedure 
 A team of key stakeholders which included the principal investigator, 
nursing management, House Obstetrical Physician, Manager of Quality and 
Education, and the Chief Medical Officer was formed October 2018. The team 
reviewed the Anthem Blue Cross and Blue Shield Manual to Quality-In-Sights: 
Hospital Incentive Program (Q-HIP) which provides a report of this facilities 
performance along with data on best practice measures.  For this unit’s report, it 
was noted that an algorithm for monitoring and treating severe 
preeclampsia/eclampsia was non-existent.  The Labetalol Algorithm provided by 
ACOG (see Appendix C) was adopted in March 2019 after project proposal 
approval and was implemented into clinical practice.   
 Prior to implementation, the algorithm was presented to the lead house 
obstetrician and the Chief Medical Officer of the unit for dissemination to the 
attending physicians.  An email was sent to the attending physicians discussing 
the algorithm and the terms of the project.  The contents of the email will contain 
the algorithm, the implementation date, and the importance of their participation. 
An email was also sent out to the nursing staff with the algorithm attached.  A 
flyer was placed in the employee bathroom to notify the employees that the 
project was taking place and to have them check their emails for details. 
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Results 
From November 1, 2018 to January 31, 2019, there were 11 patients 
diagnosed with a hypertensive disorder of pregnancy.  Of these 11 patients, four 
(n=4, 36.36%) met criteria for severe preeclampsia requiring treatment due to 
blood pressure recordings.  Two (n=2, 50%) patients were treated using the 
recommended ACOG Labetalol algorithm driven by private physician orders, and 
two (n=2, 50%) of these patients were treated using other orders given by their 
attending.  Three (n=3, 75%) of the patients that received treatment delivered 
vaginally, while the other (n=1, 25%) delivered by repeat cesarean section 
(Appendix A).  
The two patients who were treated with the recommended algorithm, saw 
a decrease in both systolic and diastolic blood pressure.  The average decrease in 
systolic and diastolic blood pressure was 19 mmHg and 6.5 mmHg respectively 
(Appendix B).  The timing of blood pressure recordings to the onset of treatment 
for these two patients was an average of 37.5 minutes (Appendix C).  The two 
patients who were treated with other orders that didn’t follow the Labetalol 
algorithm had an average increase in systolic blood pressure of 3 mmHg, and an 
average decrease in diastolic blood pressure of 2 mmHg (Appendix B).  The 
average timing of treatment initiation was 49.5 minutes (Appendix C). 
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From March 1, 2019 to May 31, 2019, after algorithm implementation, 
there were 11 patients that were diagnosed with a hypertensive disorder of 
pregnancy.  Of these 11 patients, three (n=3, 27.27%) met criteria for severe 
preeclampsia requiring treatment due to blood pressure recordings.  One (n=1, 
9.09%) patient never met criteria, but orders following the algorithm were placed 
in case blood pressures became severe.  One (n=1, 33.33%) patient was treated 
with the recommended ACOG Labetalol algorithm driven by nursing personnel, 
house obstetrician, and attending physician; and two patients (n=2, 66.66%) were 
treated with other orders given by their attending.  Of the three patients that 
received treatment, one (n=1, 33.33%) patient delivered vaginally, while the other 
two (n=2, 66.66%) delivered by primary cesarean section (Appendix D).  The one 
patient who received treatment following the Labetalol algorithm saw a decrease 
in systolic blood pressure of 22 mmHg, and a decrease in diastolic blood pressure 
of 18 mmHg (Appendix E). The timing from blood pressure recording to the onset 
of treatment was 30 minutes (Appendix F). The two patients who received 
treatment using orders other than the Labetalol algorithm saw an average decrease 
in systolic blood pressure of 8.5 mmHg and saw an average increase in diastolic 
blood pressure of 7 mmHg (Appendix E). One of these patients was admitted to 
the Intensive Care Unit with a diagnosis of pulmonary edema; a known 
complication of severe preeclampsia. The average timing from blood pressure 
LABETALOL ALGORITHM  18 
 
recordings to the onset of treatment for patients that weren’t treated using the 
algorithm was 62 minutes (Appendix F).   
Discussion 
 When criteria were met for the diagnosis and treatment of preeclampsia, 
the rate of Labetalol algorithm use by physicians prior to implementation of 
algorithm introduction to the unit was 50% (Appendix G).  After algorithm 
implementation on the unit, the rate of use by physicians was 33% (Appendix H). 
The choice of algorithm use is ultimately up to the attending physician, regardless 
of nursing and house obstetrician recommendations.   
 Prior to implementation, the average time of onset of treatment was 43.5 
minutes.  After the implementation, the average time for onset of treatment was 
51.3 minutes.  The physician should be contacted if one severe blood pressure is 
obtained (≥160 mmHg systolic or ≥110 mmHg diastolic).  If severe blood 
pressure persists for more than 15 minutes or two severe pressures are obtained 
within 15 minutes, treatment should be initiated.  Because of the variation in 
treatment guidelines and the potential to obtain non-consecutive severe blood 
pressure reading at various times, treatment initiation times will vary. 
 When criteria were met for treatment of severe preeclampsia prior to 
algorithm implementation, the average rate of maternal systolic blood pressure 
improvement was 8.75 mmHg.  However, an average increase of 4 mmHg was 
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seen in the diastolic blood pressure.  After the implementation period, the average 
rate of maternal systolic and diastolic blood pressure improvement was 12.3 
mmHg and 3.7 mmHg, respectively.  It is important to note that although this 
project’s algorithm was not implemented at this facility prior to March 2019, 
some attending physicians still used the algorithm to treat their patients prior to 
this date. It is also important to note that after the implementation period, not all 
physicians used the algorithm to treat their patients. This skewed the results. 
 Before algorithm implementation, the number of diagnosed preeclamptic 
patients that delivered by unplanned cesarean section was 0.  Three of these 
patients delivered vaginally (previous successful vaginal deliveries) and one 
patient delivered by repeat cesarean section.  After algorithm implementation, two 
patients delivered by unplanned cesarean section, and one patient delivered 
vaginally.  Of these three patients, the two patients who delivered by unplanned 
cesarean section were not treated with the algorithm.  The one patient who was 
treated using the algorithm had a vaginal delivery.  One patient who didn’t receive 
appropriate treatment was admitted to Intensive Care Unit with a diagnosis of 
Pulmonary Edema. 
Conclusion 
 When the Labetalol algorithm was followed during this project (both pre 
and post implementation period), there was a greater improvement in blood 
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pressure measurements compared to the patients who were treated with individual 
physician orders.  The pre and post implementation data in this project doesn’t 
give an accurate representation of how effective the algorithm is due to 
noncompliance from physicians.  Some attending physicians also used the 
algorithm under their own volition prior to unit wide implementation which also 
affected the retrospective chart review.  Post implementation data demonstrated 
that when healthcare personnel don’t use the Labetalol algorithm, the potential for 
unplanned cesarean sections occur more frequently, as well as maternal 
complications, such as ICU admissions. 
 This project should be completed again with education for both nursing 
personnel and physicians prior to implementation.  Data should also be collected 
for longer periods of time due to the small sample size at this facility.  It is critical 
for healthcare personnel to understand the importance of adopting and following 
algorithms and protocols in order to increase patient safety. There is a need for 
further education for all healthcare personnel regarding hypertensive disorders of 
pregnancy, diagnostic criteria, monitoring of these patients, and treatment using 
recommended protocols. As mentioned earlier, Clark et al.’s report (2014) 
showed a significant reduction in morbidity when order sets and protocols were 
implemented in facilities.  Nursing staff play an integral role in the assessment 
and treatment of hypertensive patients during pregnancy.  Once they assess the 
patient and determine that treatment is warranted, it is their responsibility to 
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contact the physician, report critical values, and recommend evidence-based 
treatment.  ACOG is an organization that is dedicated to the improvement of 
women’s health and encourages obstetricians to implement best practice.  The 
Labetalol algorithm is recommended by ACOG for the treatment of preeclamptic 
patients.   
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Figure 8. Rate of Labetalol Algorithm use Post-Implementation. 
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